Table 1 Baseline characteristics of the endometrioma and/or endometriosis-related pain recurrence and nonrecurrence groups
From: Risk factors for postoperative recurrence of ovarian endometriosis: long-term follow-up of 358 women
Characteristics | Recurrence group (n = 68) | Nonrecurrence group (n = 290) | χ2 | p value |
|---|---|---|---|---|
Age, y | 31.8 ± 5.0 | 32.9 ± 5.2 | 1.457 | 0.146 |
Gravida | 0 (0–4) | 1 (0–10) | 1.207 | 0.228 |
Parity | 0 (0–1) | 0 (0–2) | 2.385 | 0.018 |
BMI, kg/m2 | 20.9 ± 2.5 | 21.2 ± 2.6 | 0.814 | 0.416 |
rAFS stage | Â | Â | 3.093 | 0.377 |
 Stage I | 0 (0%) | 1 (0.3%) |  |  |
 Stage II | 3 (4.4%) | 7 (2.4%) |  |  |
 Stage III | 20 (29.4%) | 113 (39.2%) |  |  |
 Stage IV | 45 (66.2%) | 167 (58.0%) |  |  |
Largest-diameter endometrioma, cm | ||||
 Left | 5.6 ± 1.9 | 5.4 ± 2.2 | −0.707 | 0.481 |
 Right | 5.7 ± 2.0 | 5.2 ± 1.8 | −1.631 | 0.104 |
CA125, U/ml | 99.23 ± 89.72 | 100.37 ± 228.61 | 0.038 | 0.970 |
Dysmenorrhea, VAS | 7 (0–10) | 5 (0–10) | −3.018 | 0.003 |
Extent of dysmenorrhea | Â | Â | 15.420 | 0.001 |
 None | 4 (5.9%) | 81 (27.9%) |  |  |
 Mild | 10 (14.7%) | 40 (13.8%) |  |  |
 Moderate | 20 (29.4%) | 58 (20.0%) |  |  |
 Severe | 34 (50.0%) | 111 (38.3%) |  |  |
Duration of dysmenorrhea, m | 84 (0–360) | 24 (0–348) | −3.514 | 0.001 |
Endometrioma side | Â | Â | 3.082 | 0.214 |
 Left | 16 (23.5%) | 95 (32.8%) |  |  |
 Right | 20 (29.4%) | 62 (21.4%) |  |  |
 Bilateral | 32 (47.1%) | 133 (45.9%) |  |  |
Obliteration of cul-de-sac | Â | Â | 3.307 | 0.191 |
 Absent | 13 (19.1%) | 81 (27.9%) |  |  |
 Partial | 18 (26.5%) | 84 (29.0%) |  |  |
 Complete | 37 (54.4%) | 125 (43.1%) |  |  |
Leiomyoma | 18 (26.5%) | 46 (16.0%) | 5.057 | 0.044 (0.044) |
Deep infiltrating endometriosis | 41 (63%) | 149 (51.4%) | 1.758 | 0.224 |
Adenomyosis | 34 (50.0%) | 108 (37.4%) | 4.059 | 0.044 (0.044) |
Postoperative dysmenorrhea relief | 55 (87.3%) | 8 (90.0%) | 1.770 | 0.413 |
Infertility | Â | Â | 2.408 | 0.300 |
 Primary | 11 (16.2%) | 32 (11.0%) |  |  |
 Secondary | 6 (8.8%) | 17 (5.9%) |  |  |
Operation | Â | Â | 0.705 | 0.590 |
 Cystectomy | 65 (95.6%) | 21 (72%). |  |  |
 Salpingo-oophorectomy | 3 (4.4%) | 269 (92.8%) |  |  |
Postoperative pregnancy | 24 (35.3%) | 113 (39.0%) | 0.611 | 0.894 |
Postoperative medication | Â | Â | 11.066 | 0.026 |
 None | 0 (0%) | 12 (4.1%) |  |  |
 OCP | 1 (1.5%) | 11 (3.8%) |  |  |
 Mirena | 1 (1.5%) | 13 (4.5%) |  |  |
 GnRHa with LNG-IUD | 9 (13.2%) | 69 (23.8%) |  |  |
 GnRHa without LNG-IUD | 57 (83.8%) | 185 (63.8%) |  |  |
Duration of follow-up | 83 (60–120) | 85 (60–116) | −0.459 | 0.646 |